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Background:  Coxsackievirus  B3  (CVB3)  is  a common  cause  of  myocarditis  and  dilated  cardiomyopathy.
CVB3  3C  protease  (3CP)  cleaves  the  viral  polyprotein  during  replication.  We tested  whether  a  water
soluble  3CP inhibitor  (3CPI)  had  antiviral  effects  in a  chronic  myocarditis  model.
Methods:  Chronic  myocarditis  was  established  using  DBA/2  strain  mice.  Starting  on  post-infection  (p.i)
day 3,  CVB3-infected  mice  (n = 41)  were  treated  with  3CPI  by daily  intraperitoneal  (i.p.)  injection  at  a
concentration  of 50 M (1.7  mg/kg/day)  per  day  for  3  consecutive  days.  Additional  mice  (n =  49)  were
injected  with  PBS  as a  control.
Results:  The  5-week  survival  rate  was  signiﬁcantly  higher  with  3CPI  treatment  (82.3% versus  47.9%;
P  <  0.05).  Organ  virus  titers  at  day  3  and  7 and  myocardial  damage  were  signiﬁcantly  lower  in  3CPI-treated
mice.  Echocardiography  at day  31  indicated  strong  protection  of  heart  function  by  3CPI  (FS, 51.2 ±  1.5
versus  26.1  ± 1.5%;  P  <  0.001).  Hemodynamic  measurements  indicated  that  3CPI  treatment  markedlyhronic reduced  CVB3-induced  LV dysfunction  on day  31 (dP/dTmax,  5302  ±  352  versus  4103  ± 408  mmHg/s,
P  <  0.05;  dP/dTmin,  −3798  ±  212  versus  −2814 ± 206 mmHg/s,  P  <  0.01).
Conclusions:  Water  soluble  3CPI  was  delivered  through  i.p. injection  after  CVB3  infection.  This agent
preserved  heart function  and  decreased  organ  viral  titers  and  myocardial  damage.  Soluble 3CPI  may be
beneﬁcial  in  the  treatment  of cardiomyopathy  associated  with  enterovirus  infection.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. IntroductionEnteroviruses of the Picornaviridae family, particularly Cox-
ackievirus B3 (CVB3), are considered among the most common
tiological agents of myocarditis. Although most enterovirus infec-
ions are subclinical, acute myocardial inﬂammation can induce
Abbreviations: 3CP, 3C protease; 3CPI, 3CP inhibitor; AST, aspartate aminotrans-
erase; ALT, alanine aminotransferase; CAR, Coxsackie and Adenovirus receptor;
VB3, Coxsackievirus B3; DCM, dilated cardiomyopathy; FS, fractional shortening;
RAP, IL-1 receptor antagonist protein; LV, left ventricular; LVIDs, LV internal dimen-
ion in systole; LVIDd, LV internal dimension in diastole; PV, pressure–volume; TnI,
roponin I.
∗ Corresponding author at: Cardiac and Vascular Center, Samsung Medical Center,
epartment of Medicine, Sungkyunkwan University School of Medicine, 81 Irwon-
o,  Kangnam-Ku, Seoul 135-710, South Korea. Tel.: +82 2 3410 3448;
ax: +82 2 3410 3849.
E-mail address: esjeon1107@gmail.com (E.-S. Jeon).
ttp://dx.doi.org/10.1016/j.virusres.2014.11.030
168-1702/© 2014 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/3.0/).
severe arrhythmias and sudden cardiac death, and may  lead to
the development of a chronic myocarditis and dilated cardiomy-
opathy (DCM) (Cooper, 2002). We  reported previously on the
antiviral effects of several possible drugs in an experimental model
of CVB3-induced acute myocarditis in Balb/C mice. IL-1 recep-
tor antagonist protein (IRAP), Coxsackie and Adenovirus receptor
(CAR) antagonist protein gene therapy, and 3C protease inhibitor
(3CPI) were tested in a model of acute severe myocarditis in the
Balb/C strain (Lim et al., 2002, 2006; Yun et al., 2012). We  also
reported on the antiviral activity of water-insoluble CVB3 3CPI dis-
solved in 100% dimethyl sulfoxide (DMSO), which was delivered to
the subcutaneous region by an implanted micro-osmotic pump in
Balb/C mice. This formulation of 3CPI effectively suppressed CVB3-
induced myocardial damage and reduced mortality (Yun et al.,
2012), but we  encountered limitations in the delivery of water-
insoluble 3CPI and the timing of drug administration after CVB3
infection.
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. Generation of a water-soluble coxsackievirus 3C protease inhibitor (3CPI). (A) The original structure of 3CPI (9b) was modiﬁed by various hetero-rings to improve
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(olubility. The naphthalene group (Open Square) was replaced with quinoline, is
onﬁrmed following previously reported methods. (B) The solubility of newly gene
elected  test chemical, named 3CPI(S2) (LDD1588), displayed a strong anti-viral eff
Experimental models of chronic CVB3-induced myocarditis in
arious mouse strains have been used to explore the pathogenesis
f human myocarditis (Herskowitz et al., 1985; Huber and Lodge,
986; Khatib et al., 1987; Koide et al., 1992). Among these, the
BA/2 strain offers a speciﬁc model of human chronic myocarditis
haracterized by delayed virus replication and propagation in the
eart, because susceptibility to viral infection is lower than that of
alb/C. The correlation between viral replication and myocardial
amage has been studied at the onset of chronic murine CVB3-
nduced myocardial infection (Kandolf et al., 1993). The Balb/C
odel has a very short viremic phase, making it impossible to
eliver the drug at the appropriate time (Lim et al., 2002). To
vercome the limitations of the acute Balb/C mice model and
ater-insoluble 3CPI for delivery, we re-established a chronic CVB3
yocarditis model using DBA/2 mice and produced water-soluble
CPI (LDD1588) by modifying the 3CPI-9b chemical structure (Yun
t al., 2012). In this report, we show that the water-soluble 3CPI,
hich was injected intraperitoneally for 3 days from post-infection
p.i.) day 3, had strong antiviral effects. 3CPI markedly inhibited
irus replication, which was reﬂected in decreased virus titers in
arious organs, and less myocardial damage, and subsequently
educed mortality. 3CPI treatment also prevented the progression
rom post-myocarditis remodeling to DCM.
. Materials and methods
.1. VirusCVB3 was derived from the infectious cDNA copy of the car-
iotropic H3 variant of CVB3 (CVB3-H3). Viral titer was  determined
y plaque-forming assay in HeLa cells as described previously
Knowlton et al., 1996; Lim et al., 2012).line, and benzoimidazole. The enzyme activity of each chemical compound was
 3CPI and anti-viral effects were conﬁrmed by cell viability tests in HeLa cells. The
at was similar to the previously used insoluble 3CPI (9b).
2.2. Development of water-soluble 3CPI
We  previously reported a strong anti-enteroviral effect of a 3CPI
(Yun et al., 2012) that had to be dissolved in DMSO. To improve
solubility, we  modiﬁed the R-composition of a previously water-
insoluble 3CPI (9b structure) (Fig. 1A) (Kim et al., 2012).
2.3. Screening water soluble 3CPIs
We  conﬁrmed the solubility of water-soluble 3CPIs and antiviral
efﬁciency in an in vitro cell culture system. Brieﬂy, 5 × 105 HeLa
cells were infected with CVB3-H3 at an m.o.i. of 1 (multiplicity of
infection = 1). CVB3-H3 and the modiﬁed 3CPIs were added. After
24 h incubation, 15 l of the cell proliferation reagent supplied with
the Cell Counting Kit 8 (Dojindo Labs, Tokyo, Japan) was added, and
the cells were incubated for an additional 2 h. Absorbance at 450 nm
was then measured on a microplate reader. Uninfected HeLa cells
were used as a control and the values for the controls were set
arbitrarily to 100. The data are presented as mean ± SEM from three
independent experiments (Yun et al., 2012). The 3CPI (S2) chemical
was selected as the best candidate for the in-vivo experiments and
named LDD1588 (Fig. 1B).
2.4. Murine chronic viral myocarditis model
The animal experimental protocols used in this study conform
to the Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No. 85–23,
revised 1996). All procedures were reviewed and approved by
the Institutional Animal Care and Use Committee of Samsung
Biomedical Research Institute (SBRI). SBRI is accredited by the Asso-
ciation for Assessment and Accreditation of Laboratory Animal Care
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Fig. 2. Chronic myocarditis model in DBA/2 mice. (A) Changes of organ viral titers by PFU assay. Organ viral titers were highest at day 7 and infectious virus was detected
on  p.i. day 21. (B) Organ injuries estimated by TnI and AST/ALT using pooled sera at p.i. days 3, 7, 14 and 31. Serum TnI level was  highest at day 7 and remained elevated
during  the experimental time period up to p.i. day 31. AST/ALT levels were elevated to day 21 in a pattern that was  delayed compared to TnI. (C) Cardiac inﬂammation was
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y  pancreatitis (m–p). Scale bars indicate 100 m (a–h and m–p) or 200 m (i–l). D
ndependent experiments.nternational and abides by the Institute of Laboratory Animal
esources guide.
In acute myocarditis model as in Balb/C mice, infectious virus
s detected by day 10 post-infection. The mortality by 3 weeksd by von Kossa (e–h) and Evans blue stain (i–l). Virus replication was represented
e presented as the mean plus or minus the standard error of the mean from threeis over 90%, and mice usually died before developing the heart
failure phenotype. To develop post infectious dilated cardiomy-
opathy phenotype, we used the DBA/2 strain instead of the Balb/C
strain. Five-week-old male DBA/2 mice were inoculated on day 0
4 B.-K. Lim et al. / Virus Research 199 (2015) 1–8
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tig. 3. Survival curves and echocardiography in the DBA/2 myocarditis model. (A)
nfected DBA/2 mice showed higher left ventricular internal dimensions in systole (
ice.  Data are presented as the mean plus or minus the standard error of the mean
y intraperitoneal injection of 2 × 103 plaque-forming units (PFUs)
f CVB3-H3. Mice were euthanized via cervical dislocation after
nesthesia by ketamine injection (100 mg/kg) and the serum and
arious organs (heart, liver, spleen, and pancreas) were collected
n p.i. days 3, 7, 14, 21, and survived mice were leaved to observe
he heart failure development at days 31. To evaluate myocardial
amage, mice were injected with Evans blue dye for 8 h before
uthanasia. Viral titer was  measured by a plaque-forming assay
n samples from the heart and pancreas. Cardiac damage and liver
amage were assessed by measuring the levels of troponin I (TnI),
spartate aminotransferase (AST), and alanine aminotransferase
ALT) in the serum using the Fujiﬁlm Dri-Chem 3000 system accord-
ng to the manufacturer’s instructions (Fujiﬁlm, Seoul, Korea).
.5. Histopathology and organ viral titers
The heart and pancreas were collected and viral titers measured
n days 3, 7, 14, and 21 after intraperitoneal (i.p) CVB3-H3 infection.
he basal parts of the hearts were homogenized in DMEM medium
ith 5% fetal bovine serum, and supernatant viral titers were mea-
ured by plaque-forming assay. The apical parts of the hearts were
xed in 10% formalin, embedded in parafﬁn wax, sectioned at m,  and stained with hematoxylin–eosin (H&E) for inﬂammation
etection or Picrosirius red and von Kossa staining for ﬁbrosis and
yocardium disruption. The extent of inﬂammation was  graded in
he tissue sections, and the percent area of myocardial ﬁbrosis wasurvival rate of CVB3-H3 infected DBA/2 mice on p.i. day 31 was in 52%. (B) CVB3-
) and in diastole (LVIDd), and lower fractional shortenings (FS) compared to control
 three independent experiments. *P < 0.05, ***P < 0.001
evaluated using the NIH image quantiﬁcation method (Lim et al.,
2008).
2.6. Antiviral effect of 3CPI in the DBA/2 myocarditis model
To test the antiviral effects of water-soluble 3CPI (LDD-1588),
either 3CPI at 50 M (1.7 mg/kg/day) or saline alone (control) was
injected i.p. for 3 consecutive days from p.i. day 3 (CVB3 + 3CPI
group, n = 41; CVB3 group, n = 49). Mice were euthanized via cervi-
cal dislocation after anesthesia by ketamine injection (100 mg/kg),
and the serum, heart, liver, spleen, and pancreas were collected as
described above. These mice (CVB3 group, n = 4; CVB3 + 3CPI group,
n = 5 for each day) were excluded from the survival analysis. Mice
were monitored two  times a day.
2.7. Mouse echocardiography
M-mode echocardiograms were performed in CVB3-H3 infected
mice treated with or without 3CPI. Adult mice were anesthetized
with 1% isoﬂurane on p.i. day 31 and then subjected to echocar-
diography as described previously (Lim et al., 2008; Xiong et al.,
2007).2.8. Hemodynamic measurements
At 31 days after CVB3 infection with or without water-soluble
3CPI, hemodynamic measurements were made using a microtip
B.-K. Lim et al. / Virus Research 199 (2015) 1–8 5
Fig. 4. Antiviral effect of water-soluble 3CPI (LDD1588) in a chronic myocarditis model. (A) The ﬁve-week survival rate of the CVB3 + 3CPI group was signiﬁcantly higher
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ressure–volume (PV) catheter (SPR-838, Millar Instruments;
ouston, TX, USA). Brieﬂy, mice were anesthetized using a mixture
f ketamine (100 mg/kg) and xylazine (5 mg/kg). The animals were
ntubated with a blunt 21-gauge needle using the tracheotomy
ethod and ventilated with a custom-designed constant-pressure
entilator at 75 breaths/min using room air. An anterior thora-
otomy was performed, and a small apical stab was made with
 27-gauge needle to expose the left ventricular (LV) apex. The
icrotip catheter was inserted retrogradely into the LV cavity along
he cardiac longitudinal axis until stable PV loops were obtained.
ice were euthanized via cervical dislocation after recording. Loops
ere acquired after 20 min  of stabilization with the ventilator
urned off for 5–10 s. The sampling rate was 1000/s using the ARIA
–V conductance system (Millar Instruments) coupled to a Pow-
rLab 16/30A/D converter (AD Instruments, Mountain View, CA,
SA).
.9. Statistics
The data are presented as the mean ± SEM. Differences in
easured parameters between control and target groups were
xamined using the Mann–Whitney nonparametric t-test (Graph-
ad Prism3.0 for Windows, GraphPad Software, La Jolla, CA, USA).
urvival rates were analyzed using the Kaplan–Meier method. A
-value < 0.05 was considered signiﬁcant.
. Results.1. Phenotype of chronic viral myocarditis in DBA/2 mice
We  re-established a CVB3-induced chronic viral myocarditis
odel in the DBA/2 strain. Viral titers peaked in the heart andd pancreas were highest on day 7 in the DBA/2 chronic myocarditis model, and
s the mean plus or minus the standard error of the mean from three independent
pancreas on p.i. day 7 and decreased quickly (Fig. 2A), suggesting
that virus proliferation was  delayed in the DBA/2 strain compared
with the Balb/C strain, in which virus titers peak on p.i. day 3.
Changes in serum TnI level were similar to those of the heart viral
titers up to p.i. day 21, but serum TnI level remained elevated to the
end of the experiment on p.i. day 31. AST/ALT levels were elevated
to p.i. day 21, but the pattern was delayed compared to TnI (Fig. 2B),
possibly reﬂecting ongoing organ damage or remodeling after viral
injury in the heart and liver. Histological myocardial damage as
assessed by Evans blue stain (Fig. 2C, i–l) and necrotic lesions with
calcium (Ca2+) uptake continued expanding through p.i. day 21 (as
assessed by H&E stain (Fig. 2C, a–d) and von Kossa stain (Fig. 2C,
e–h)). Taken together, these ﬁndings demonstrate that pathologi-
cal changes in the hearts of CVB3-infected DBA/2 mice progressed
to DCM through a remodeling process.
3.2. Survival curves and echocardiography in a DBA/2
myocarditis model
The survival rate of CVB3-H3 infected DBA/2 mice on p.i.
day 31 was 52% (9/20). Mice died between p.i. days 10 and 20
(Fig. 3A). We  performed echocardiography to evaluate heart size
and function on p.i. day 31. The LV internal dimension in sys-
tole (LVIDs), diastole (LVIDd), and fractional shortening (FS) were
measured in CVB3-infected DBA/2 mice and control mice. CVB3-
infected DBA/2 mice had larger LVIDs and LVIDd and smaller FS
compared to control mice (LVIDs, 1.68 ± 0.15 versus 2.65 ± 0.12,
LVIDd, 3.15 ± 0.07 versus 3.59 ± 0.14, FS, 47.16 ± 3.78 versus
26.32 ± 1.1 in CVB3-infected and control mice, respectively (n = 5))
(Fig. 3B).
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Fig. 5. 3CPI prevented CVB3-induced myocardial damage. (A) Myocardial inﬂammation and damages were evaluated by H&E and von Kossa stain. At day 7, inﬂammation
and  myocardial Ca2+ uptake were markedly lower in the CVB3 + 3CPI group (a–d). On day 21, the area of Ca2+ deposition was also signiﬁcantly lower in the CVB3 + 3CPI group
(e–h).  The pancreas was not different between groups (i–j). In CVB3 infected mice, LV was  progressively dilated. This post-myocarditic LV remodeling was inhibited by 3CPI
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f  3CPI. Data are presented as the mean plus or minus the standard error of the mea
a–j)  and 1 mm (k–l).
.3. Antiviral effect of 3CPI in the chronic myocarditis model
The 5-week survival rate of the CVB3-infected control group was
7.9%. The survival rate was signiﬁcantly higher in the CVB3 + 3CPI
roup than in the CVB3 group (82.3% versus 47.9%; P < 0.05)
Fig. 4A). In this DBA/2 myocarditis mouse model, viral titers in
he heart and pancreas were highest on p.i. day 7, and the organ
iral titers were signiﬁcantly lower in CVB3 + 3CPI group than in
he untreated controls (heart, 3.8 ± 0.1 versus 8.7 ± 0.1 log PFU/mg;
 < 0.05; pancreas, 5.7 ± 0.1 versus 9.0 ± 0.1 log PFU/mg; P < 0.05)
Fig. 4B).
.4. Histopathology
Myocardial inﬂammation and damage were evaluated by H&E
nd von Kossa staining on p.i. days 7 and 21. On day 7, inﬂammation
nd myocardial Ca2+ uptake were markedly lower in CVB3 + 3CPI
ice than in CVB3 mice (Fig. 5A, a–d). On p.i. day 21, the area
f Ca2+deposition was also signiﬁcantly lower in the CVB3 + 3CPI
roup (Fig. 5A, e–h and B), but there were no differences in the
ancreas (Fig. 5A, i and j). In CVB3 infected mice, the left ventricle
as progressively dilated, reﬂecting post-myocarditic LV remodel-
ng causing the typical phenotype of DCM. This post-myocarditic
V remodeling was inhibited by 3CPI treatments (Fig. 5A, k and
), providing strong evidence that the new water-soluble 3CPI
ecreased myocardial injury by inhibiting viral proliferation and
onsequently prevented LV remodeling from progressing to LV
ilatation. NIH image quantiﬁcation method were signiﬁcantly decreased by administration
 three independent experiments. **P < 0.01, ***P < 0.001. Scale bar indicate 100 m
3.5. Preservation of heart function by 3CPI after CVB3 infection
Echocardiography on p.i. day 31 also showed a strong preser-
vation of heart function by 3CPI treatment in CVB3-H3 infection.
LV function was  signiﬁcantly preserved (FS, 51.2 ± 1.5% versus
26.1 ± 1.5%; P < 0.001; n = 4 each group) (Fig. 6A). Ninety per-
cent of CVB3-infected mice not treated with 3CPI showed LV
dilatation. Hemodynamic measurements using a microtip PV
catheter demonstrated that 3CPI treatment markedly reduced
CVB3-induced LV dysfunction compared with controls on p.i. day
31 (dP/dTmax, 5302 ± 352 versus 4103 ± 408 mmHg/s; P < 0.05;
dP/dTmax, −3798 ± 212 versus −2814 ± 206 mmHg/s; P < 0.01)
(Fig. 6B).
4. Discussion
In this work, we  successfully re-established a model of chronic
viral myocarditis that can be used to study antiviral drugs for the
subacute treatment of viral myocarditis and may  be applicable
to the clinical course of the condition in humans. In our study, a
water-soluble 3CPI, LDD1588, that was injected intraperitoneally
during the subacute viremic phase signiﬁcantly decreased virus
proliferation and prevented progression from post-myocarditic LV
remodeling to DCM.Many antiviral drugs have been tested against CVB3-induced
myocarditis in Balb/C mice, and the results have suggested that
acute virus proliferation induces the cellular immune response,
which leads to direct cardiac injury. Although cellular immunity
B.-K. Lim et al. / Virus Research 199 (2015) 1–8 7
Fig. 6. 3CPI preserved left ventricular function. (A) Echocardiography on p.i. day 31 showed the strong anti-remodeling effect of 3CPI, n = 4 each group (FS, 51.2 ± 1.5 versus
26.1  ± 1.5%; P < 0.001; control, virus non-infected). (B) Hemodynamic measurement was  performed by microtip PV catheter. 3CPI administration signiﬁcantly preserved
heart  function (dP/dTmax, 5302 ± 352 versus 4103 ± 408 mmHg/s, P < 0.05; dP/dTmin, −3798 ± 212 versus −2814 ± 206 mmHg/s, P < 0.01). Cardiac output displayed normal
levels.  Data are presented as the mean plus or minus the standard error of the mean from 3 independent experiments. LVIDd, left ventricular diastolic dimension; LVIDs, left
v  0.001
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fentricular systolic dimension; FS, fractional shortening, NS P > 0.05, *P < 0.05, ***P <
nitiates acute myocarditis in Balb/C mice, myocyte-reactive anti-
odies are detected in the serum of infected animals during periods
f inﬂammation and cardiac necrosis (Yun et al., 2012). We  previ-
usly reported that early inﬂammatory cytokine receptor blockers
nd the virus receptor have an antiviral effect (Kim et al., 2006;
im et al., 2002, 2006). Pinkert et al. (2009) also showed antiviral
ffects using an adenovirus system that expressed soluble CAR-Fc,
ut the use of a viral vector system has not been fully established
or clinical applications..
We reported previously that CVB3 3CPIs have an antiviral effect
against CVB3 and several enteroviruses (Yun et al., 2012). We  found
that CVB3 3CPI inhibited enterovirus 3C protease activity in vitro,
suppressed the proliferation of CVB3 in cell culture, and had a ther-
apeutic effect against acute murine myocarditis. At the same time,
we encountered some limitations in transferring the results to clin-
ical applications. First, because of its chemical composition, the
initial 3CPI was not water soluble and so could not be injected
directly into the body. Second, because Balb/C mice are highly
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usceptible to CVB3 and become too ill to manipulate from p.i. day
, the antiviral drug needed to be administered at the same time as
he virus infection, on day 0. In most clinical situations, an antiviral
rug would be administered only after the patient becomes ill. A
odel of chronic myocarditis with a longer time course was  needed
o overcome the limitations of this previous model.
To do so, we re-established a chronic myocarditis model
sing the DBA/2 strain of mice. Susceptibility to Coxsackievirus-
nduced myocarditis differs considerably between strains of mice
Wolfgram et al., 1986). Most strains develop severe acute
yocarditis, and only a few special strains of mice develop
hronic myocarditis that mimics human viral myocarditis and DCM
Wolfgram et al., 1985). Chronic CVB3-induced myocarditis has
een described previously in DBA/2 strains with histopathologi-
al features similar to those observed in the heart in humans. In
ur CVB3-infected DBA/2 mouse model, replication of viral parti-
les correlated strongly with pathological changes associated with
hronic myocarditis on p.i. day 31. In previous studies, the viral
iters in the myocardium were signiﬁcantly lower in the chronic
eriod than in the acute period, and the myocardium showed per-
istent CVB3 infection during the chronic period (Klingel et al.,
992; Klingel and Kandolf, 1993; Sato et al., 1994). Our results are
onsistent with these earlier experimental data (Figs. 2 and 3). In
ur experiments, about 52% of DBA/2 mice survived until p.i. 31
ays. Echocardiography showed that the LV chamber was dilated,
s seen typically in DCM as a result of post-myocarditic remodel-
ng. The serum TnI level peaked at the same time as the organ viral
iters on p.i. day 7. TnI level increased again on p.i. day 31, indicating
ersistent myocardial damage. These ﬁndings strongly suggest that
VB3-induced myocarditis had progressed from post-myocarditic
emodeling to DCM in this DBA/2 mouse model.
Administration of the water-soluble 3CPI (LDD1588) in this
BA/2 mouse model of chronic myocarditis prevented CVB3 pro-
iferation and post-myocarditic remodeling, and preserved heart
unction. These ﬁndings suggest that the water-soluble 3CPI, LDD-
588, has potential in clinical antiviral treatment. 3CPI can be
elivered intraperitoneally on p.i. day 3 and signiﬁcantly inhibits
irus proliferation in the heart and pancreas. Reducing myocardial
amage by limiting viral proliferation in the heart might protect
gainst progression from post-myocarditic LV remodeling to DCM.
In summary, we re-established the chronic CVB3 myocarditis
odel in DBA/2 mice and produced water-soluble 3CPI (LDD1588).
he water-soluble 3CPI was injected intraperitoneally for 3 days
rom p.i. day 3 and had strong antiviral effects by markedly
nhibited virus replication. This agent also decreased virus titers
n various organs, myocardial damage, and mouse mortality. In
ddition, LDD1588 treatment prevented the progression from post-
yocarditic remodeling to DCM. These ﬁndings strongly suggest
hat soluble 3CPI may  be beneﬁcial in the treatment of cardiomy-
pathy associated with enterovirus infection.
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